Rate and Risk Factors for Severe/Critical Disease Among Fully Vaccinated Persons With Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a High-Risk National Population

被引:25
作者
Butt, Adeel A. [1 ,2 ,3 ,4 ]
Yan, Peng [1 ]
Shaikh, Obaid S. [1 ,5 ]
Mayr, Florian B. [1 ,6 ]
Omer, Saad B. [7 ]
机构
[1] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA
[2] Weill Cornell Med Coll, Dept Med, Doha, Qatar
[3] Weill Cornell Med Coll, Dept Populat Hlth Sci, Doha, Qatar
[4] Hamad Med Corp, Doha, Qatar
[5] Univ Pittsburgh, Dept Med, Med Ctr, Pittsburgh, PA USA
[6] Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA USA
[7] Yale Sch Med, Yale Inst Global Hlth, New Haven, CT USA
关键词
breakthrough infection; outcomes; SARS-CoV-2; vaccination;
D O I
10.1093/cid/ciab1023
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections after vaccination have been reported. Outcomes among persons with breakthrough infection are poorly understood. Methods We identified all veterans with a confirmed SARS-CoV-2 infection >14 days after the second dose of an mRNA vaccine between 15 December 2020 and 30 June 2021 and propensity score-matched unvaccinated controls with SARS-CoV-2 infection. The primary outcome was severe/critical disease, defined as admission to an intensive care unit, need for mechanical ventilation, or death within 28 days of diagnosis or during index hospitalization. Results Among 502 780 vaccinated and 599 974 unvaccinated persons, there were 2332 (0.5%) breakthrough infections in the vaccinated group and 40 540 (6.8%) infections in the unvaccinated group over a follow-up period of 69 083 person-days in each group. Among these groups, we identified 1728 vaccinated persons with breakthrough infection (cases) and 1728 propensity score-matched unvaccinated controls with infection. Among the former, 95 (5.5%) persons met the criteria for severe/critical disease, while 200 (11.6%) persons met the criteria among the latter group. The incidence rate for severe/critical disease per 1000 person-days (95% confidence interval [CI]) was .55 (.45-.68) among vaccinated persons with breakthrough infection and 1.22 (1.07-1.41) among the unvaccinated matched controls who developed infection (P < .0001). Risk was higher; the hazard ratio (95% CI) with increasing age per 10-year increase was 1.25 (1.11-1.41); for those with >4 comorbidities, it was 2.85 (1.49-5.43), while being vaccinated was associated with strong protection against severe/critical disease (HR, 0.41; 95% CI: .32-.52). Conclusions The rate of severe/critical disease is higher among older persons and those with >4 comorbidities but lower among fully vaccinated persons with breakthrough infection compared with unvaccinated controls who develop infection. Severe acute respiratory syndrome coronavirus 2 breakthrough infections occurred in 0.5% of vaccinated persons but were less severe than infections in propensity score-matched unvaccinated persons.
引用
收藏
页码:E849 / E856
页数:8
相关论文
共 29 条
[1]   Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants [J].
Abu-Raddad, Laith J. ;
Chemaitelly, Hiam ;
Butt, Adeel A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (02) :187-189
[2]   Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer [J].
Addeo, Alfredo ;
Shah, Pankil K. ;
Bordry, Natacha ;
Hudson, Robert D. ;
Albracht, Brenna ;
Di Marco, Mariagrazia ;
Kaklamani, Virginia ;
Dietrich, Pierre-Yves ;
Taylor, Barbara S. ;
Simand, Pierre-Francois ;
Patel, Darpan ;
Wang, Jing ;
Labidi-Galy, Intidhar ;
Fertani, Sara ;
Leach, Robin J. ;
Sandoval, Jose ;
Mesa, Ruben ;
Lathrop, Kate ;
Mach, Nicolas ;
Shah, Dimpy P. .
CANCER CELL, 2021, 39 (08) :1091-+
[3]  
[Anonymous], 2021, VETERANS AFFAIRS
[4]   Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J].
Baden, Lindsey R. ;
El Sahly, Hana M. ;
Essink, Brandon ;
Kotloff, Karen ;
Frey, Sharon ;
Novak, Rick ;
Diemert, David ;
Spector, Stephen A. ;
Rouphael, Nadine ;
Creech, C. Buddy ;
McGettigan, John ;
Khetan, Shishir ;
Segall, Nathan ;
Solis, Joel ;
Brosz, Adam ;
Fierro, Carlos ;
Schwartz, Howard ;
Neuzil, Kathleen ;
Corey, Larry ;
Gilbert, Peter ;
Janes, Holly ;
Follmann, Dean ;
Marovich, Mary ;
Mascola, John ;
Polakowski, Laura ;
Ledgerwood, Julie ;
Graham, Barney S. ;
Bennett, Hamilton ;
Pajon, Rolando ;
Knightly, Conor ;
Leav, Brett ;
Deng, Weiping ;
Zhou, Honghong ;
Han, Shu ;
Ivarsson, Melanie ;
Miller, Jacqueline ;
Zaks, Tal .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :403-416
[5]   Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant [J].
Bernal, Jamie Lopez ;
Andrews, Nick ;
Gower, Charlotte ;
Gallagher, Eileen ;
Simmons, Ruth ;
Thelwall, Simon ;
Stowe, Julia ;
Tessier, Elise ;
Groves, Natalie ;
Dabrera, Gavin ;
Myers, Richard ;
Campbell, Colin N. J. ;
Amirthalingam, Gayatri ;
Edmunds, Matt ;
Zambon, Maria ;
Brown, Kevin E. ;
Hopkins, Susan ;
Chand, Meera ;
Ramsay, Mary .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (07) :585-594
[6]   Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination in a high-risk national population [J].
Butt, Adeel A. ;
Yan, Peng ;
Shaikh, Obaid S. ;
Mayr, Florian B. .
ECLINICALMEDICINE, 2021, 40
[7]   Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination [J].
Butt, Adeel A. ;
Khan, Tasnim ;
Yan, Peng ;
Shaikh, Obaid S. ;
Omer, Saad B. ;
Mayr, Florian .
JOURNAL OF INFECTION, 2021, 83 (02) :246-247
[8]   SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting [J].
Butt, Adeel A. ;
Omer, Saad B. ;
Yan, Peng ;
Shaikh, Obaid S. ;
Mayr, Florian B. .
ANNALS OF INTERNAL MEDICINE, 2021, 174 (10) :1404-+
[9]   Mortality is not increased in SARS-CoV-2 infected persons with hepatitis C virus infection [J].
Butt, Adeel A. ;
Yan, Peng ;
Chotani, Rashid A. ;
Shaikh, Obaid S. .
LIVER INTERNATIONAL, 2021, 41 (08) :1824-1831
[10]   Rates and characteristics of SARS-CoV-2 infection in persons with hepatitis C virus infection [J].
Butt, Adeel A. ;
Yan, Peng .
LIVER INTERNATIONAL, 2021, 41 (01) :76-80